Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
Upon termination of a clinical trial that uses interim evaluations to determine whether the trial can be stopped, a proper statistical analysis must account for the interim evaluations. For example, in a group-sequential design where the efficacy of a treatment regimen is evaluated at interim stages, and the opportunity to stop the trial based on positive efficacy findings exists, the terminal p-value, point estimate, and confidence limits of the outcome of interest must be adjusted to eliminate bias. While it is standard practice to adjust terminal statistical analyses due to opportunities to stop for "positive" findings, adjusting due to opportunities to stop for "negative" findings is also important. Stopping rules for negative findings are particularly useful when monitoring a specific rare serious adverse event in trials designed to show safety with respect to the event. In these settings, establishing conservative stopping rules are appropriate, and therefore accounting for the interim monitoring can have a substantial effect on the final results. Here I present a method to account for interim safety monitoring and illustrate its usefulness. The method is demonstrated to have advantages over methodology that does not account for interim monitoring.
Dallas
Michael J
MJ
Merck Research Laboratories, North Wales, Pennsylvania 19454, USA. michael_dallas@merck.com
D002986:Clinical Trials as Topic / Q000009:adverse effects* / Q000592:standards / Q000706:statistics & numerical data*; D012449:Safety / Q000592:standards; D018401:Sample Size